Key result
Atrophy-inducing conditions, including streptozotocin-induced diabetes and dexamethasone treatment, significantly downregulate miR-23a in skeletal muscle through attenuated calcineurin/NFAT signaling and increased exosome-mediated export.
p-value: p=<0.05
Skeletal muscle atrophy downregulates miR-23a via attenuated calcineurin/NFAT signaling and increased exosomal export.
May link miR-23a loss to atrophy; hypothesis-generating for miRNA therapies in human muscle wasting.
Skeletal muscle atrophy is prevalent in chronic diseases, and microRNAs (miRs) may play a key role in the wasting process. miR-23a was previously shown to inhibit the expression of atrogin-1 and muscle RING-finger protein-1 (MuRF1) in muscle. It also was reported to be regulated by cytoplasmic nuclear factor of activated T cells 3 (NFATc3) in cardiomyocytes. The objective of this study was to determine if miR-23a is regulated during muscle atrophy and to evaluate the relationship between calcineurin (Cn)/NFAT signaling and miR-23a expression in skeletal muscle cells during atrophy. miR-23a was decreased in the gastrocnemius of rats with acute streptozotocin-induced diabetes, a condition known to increase atrogin-1 and MuRF1 expression and cause atrophy. Treatment of C2C12 myotubes with dexamethasone (Dex) for 48 h also reduced miR-23a as well as RCAN1.4 mRNA, which is transcriptionally regulated by NFAT. NFATc3 nuclear localization and the amount of miR-23a decreased rapidly within 1 h of Dex administration, suggesting a link between Cn signaling and miR-23a. The level of miR-23a was lower in primary myotubes from mice lacking the α- or β-isoform of the CnA catalytic subunit than wild-type mice. Dex did not further suppress miR-23a in myotubes from Cn-deficient mice. Overexpression of CnAβ in C2C12 myotubes prevented Dex-induced suppression of miR-23a. Finally, miR-23a was present in exosomes isolated from the media of C2C12 myotubes, and Dex increased its exosomal abundance. Dex did not alter the number of exosomes released into the media. We conclude that atrophy-inducing conditions downregulate miR-23a in muscle by mechanisms involving attenuated Cn/NFAT signaling and selective packaging into exosomes.
No takes yet. Share an insight, caveat, or question.
Hudson et al. (2013) studied Skeletal muscle atrophy. Atrophy-inducing conditions (Streptozotocin or Dexamethasone) vs. Vehicle control or untreated cells was evaluated on miR-23a expression levels (p=<0.05). Atrophy-inducing conditions, including streptozotocin-induced diabetes and dexamethasone treatment, significantly downregulate miR-23a in skeletal muscle through attenuated calcineurin/NFAT signaling and increased exosome-mediated export.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: